Pharmacokinetic Profile, Safety, and Tolerability of Crisaborole Topical Ointment, 2% in Adolescents with Atopic Dermatitis: An Open-Label Phase 2a Study

Pediatric Dermatology
Wynnis L TomLee T Zane

Abstract

Phosphodiesterase-4 (PDE4) is an emerging target in treating inflammatory skin diseases. Crisaborole topical ointment, 2% is a novel, boron-based, topical PDE4 inhibitor under investigation for treatment of mild to moderate atopic dermatitis (AD). Adolescent patients aged 12 to 17 years with treatable AD lesions involving ≥ 10% to ≤ 35% body surface area (BSA) were enrolled into a phase 2a, open-label study comprising pharmacokinetic (PK), safety, tolerability, and efficacy assessments. Crisaborole topical ointment, 2% was applied twice daily to affected areas for 28 days, with dosage based on baseline treatable BSA. PK blood samples were collected on days 1, 2, 4, 6, 8, and 9. Safety assessments included adverse events (AEs), laboratory parameters, and vital signs. Efficacy assessments included the Investigator's Static Global Assessment (ISGA) score and severity of AD signs and symptoms. Twenty-three patients were enrolled; 22 completed the study (1 patient discontinued due to an AE [application site dermatitis]). PK analysis demonstrated limited exposure to crisaborole topical ointment, 2% after 8 days of dosing. Ten patients reported a total of 19 AEs, most commonly application site pain and nasopharyngitis (3 patients each...Continue Reading

Associated Clinical Trials

References

Dec 31, 2005·Journal of the American Academy of Dermatology·Ulrich R HenggeMichael J Cork
Jul 4, 2006·The Journal of Allergy and Clinical Immunology·Cezmi A AkdisUNKNOWN European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology
Jul 27, 2006·Allergy·C A AkdisUNKNOWN Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Group
Nov 11, 2006·The Journal of Investigative Dermatology·Felix M ArellanoCarle F Paul
Mar 14, 2007·Inflammation & Allergy Drug Targets·Wolfgang BäumerManfred Kietzmann
Apr 4, 2008·The New England Journal of Medicine·Thomas Bieber
Jul 3, 2013·Journal of Cutaneous Medicine and Surgery·Ashley O'TooleRichard Thomas
May 13, 2014·Journal of the American Academy of Dermatology·Lawrence F EichenfieldRobert Sidbury
Feb 19, 2015·JAMA Dermatology·David J MargolisWarren B Bilker
Apr 5, 2015·Journal of the American Academy of Dermatology·Laureline LegendreCarle Paul

❮ Previous
Next ❯

Citations

Jun 23, 2016·Toxicology Letters·E D Farfán-GarcíaM A Soriano-Ursúa
Jul 3, 2016·American Journal of Clinical Dermatology·Diane Wang, Lisa A Beck
May 12, 2016·The Journal of Dermatological Treatment·Jonathan I SilverbergGil Yosipovitch
Jun 6, 2017·Current Opinion in Allergy and Clinical Immunology·Beatriz CabanillasNatalija Novak
May 17, 2018·Journal of Biomaterials Science. Polymer Edition·Hye Ri LeeJin Ho Lee
Jul 31, 2018·Expert Opinion on Investigational Drugs·Kam Lun HonVivian W Y Lee
Dec 28, 2018·Expert Review of Clinical Immunology·Aisleen Diaz, Emma Guttman-Yassky
Apr 20, 2019·Expert Opinion on Pharmacotherapy·Vignesh RamachandranLindsay C Strowd
Sep 6, 2018·Current Medicinal Chemistry·Zhu YinghuaiYingjun Zhang
Feb 14, 2020·Expert Opinion on Drug Discovery·Kam Lun HonVivian W Y Lee
May 21, 2020·Journal of Clinical Pharmacology·Vivek PurohitWilliam C Ports
Jul 7, 2017·Drugs·Jusleen AhluwaliaLawrence F Eichenfield
Oct 28, 2019·The Journal of Dermatology·Ryosuke OnoVivek S Purohit
Mar 16, 2017·Expert Review of Clinical Immunology·Alice C Cheape, Dedee F Murrell
Dec 30, 2017·American Journal of Clinical Dermatology·Janelle Pavlis, Gil Yosipovitch
Jul 2, 2020·American Journal of Clinical Dermatology·Radomir ReszkeJacek C Szepietowski
Aug 17, 2019·The Journal of Allergy and Clinical Immunology·Robert BissonnetteEmma Guttman-Yassky
Nov 13, 2020·Journal of Asthma and Allergy·Danielle R DavariDean S Morrell
May 4, 2021·Frontiers in Cell and Developmental Biology·Paul M EpsteinStefan Brocke
May 21, 2021·Journal of Experimental Pharmacology·Kam Lun Ellis HonAlexander K C Leung
Aug 12, 2021·Clinical, Cosmetic and Investigational Dermatology·Zoe M LipmanGil Yosipovitch
Nov 2, 2021·Expert Review of Clinical Immunology·Giuseppe IngrasciGil Yosipovitch

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atopic Dermatitis

Atopic dermatitis is a chronic inflammatory genetically determined disease of the skin marked by increased ability to form reagin (IgE), with increased susceptibility to allergic rhinitis and asthma, and hereditary disposition to a lowered threshold for pruritus. Discover the latest research on atopic dermatitis here.